The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Pneumococcal Vaccine-Global Market Insights and Sales Trends 2025
Synopsis
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
The global Pneumococcal Vaccine market size is expected to reach US$ 7780.4 million by 2029, growing at a CAGR of 1.1% from 2023 to 2029. The market is mainly driven by the significant applications of Pneumococcal Vaccine in various end use industries. The expanding demands from the Child and Adult, are propelling Pneumococcal Vaccine market. PPSV 23, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the PCV 7/13 segment is estimated at % CAGR for the next seven-year period.
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by End User. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pneumococcal Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pneumococcal Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pneumococcal Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pneumococcal Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pneumococcal Vaccine covered in this report include Pfizer, GSK, MSD, Sanofipasteur and CDIBP, etc.
The global Pneumococcal Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
Global Pneumococcal Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pneumococcal Vaccine market, Segment by Type:
PPSV 23
PCV 7/13
PCV 10
Global Pneumococcal Vaccine market, by End User
Child
Adult
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Pneumococcal Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Pneumococcal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by End User, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
The global Pneumococcal Vaccine market size is expected to reach US$ 7780.4 million by 2029, growing at a CAGR of 1.1% from 2023 to 2029. The market is mainly driven by the significant applications of Pneumococcal Vaccine in various end use industries. The expanding demands from the Child and Adult, are propelling Pneumococcal Vaccine market. PPSV 23, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the PCV 7/13 segment is estimated at % CAGR for the next seven-year period.
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by End User. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pneumococcal Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pneumococcal Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pneumococcal Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pneumococcal Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pneumococcal Vaccine covered in this report include Pfizer, GSK, MSD, Sanofipasteur and CDIBP, etc.
The global Pneumococcal Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
Global Pneumococcal Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pneumococcal Vaccine market, Segment by Type:
PPSV 23
PCV 7/13
PCV 10
Global Pneumococcal Vaccine market, by End User
Child
Adult
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Pneumococcal Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Pneumococcal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by End User, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Pneumococcal Vaccine Market Overview
1.1 Pneumococcal Vaccine Product Overview
1.2 Pneumococcal Vaccine Market Segment by Type
1.2.1 PPSV 23
1.2.2 PCV 7/13
1.2.3 PCV 10
1.3 Global Pneumococcal Vaccine Market Size by Type
1.3.1 Global Pneumococcal Vaccine Market Size Overview by Type (2018-2029)
1.3.2 Global Pneumococcal Vaccine Historic Market Size Review by Type (2018-2023)
1.3.3 Global Pneumococcal Vaccine Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Pneumococcal Vaccine Sales Breakdown by Type (2018-2023)
1.4.2 Europe Pneumococcal Vaccine Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Pneumococcal Vaccine Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Pneumococcal Vaccine Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Pneumococcal Vaccine Sales Breakdown by Type (2018-2023)
2 Global Pneumococcal Vaccine Market Competition by Company
2.1 Global Top Players by Pneumococcal Vaccine Sales (2018-2023)
2.2 Global Top Players by Pneumococcal Vaccine Revenue (2018-2023)
2.3 Global Top Players by Pneumococcal Vaccine Price (2018-2023)
2.4 Global Top Manufacturers Pneumococcal Vaccine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Pneumococcal Vaccine Market Competitive Situation and Trends
2.5.1 Pneumococcal Vaccine Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Pneumococcal Vaccine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pneumococcal Vaccine as of 2022)
2.7 Date of Key Manufacturers Enter into Pneumococcal Vaccine Market
2.8 Key Manufacturers Pneumococcal Vaccine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Pneumococcal Vaccine Status and Outlook by Region
3.1 Global Pneumococcal Vaccine Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Pneumococcal Vaccine Historic Market Size by Region
3.2.1 Global Pneumococcal Vaccine Sales in Volume by Region (2018-2023)
3.2.2 Global Pneumococcal Vaccine Sales in Value by Region (2018-2023)
3.2.3 Global Pneumococcal Vaccine Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Pneumococcal Vaccine Forecasted Market Size by Region
3.3.1 Global Pneumococcal Vaccine Sales in Volume by Region (2024-2029)
3.3.2 Global Pneumococcal Vaccine Sales in Value by Region (2024-2029)
3.3.3 Global Pneumococcal Vaccine Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Pneumococcal Vaccine by End User
4.1 Pneumococcal Vaccine Market Segment by End User
4.1.1 Child
4.1.2 Adult
4.2 Global Pneumococcal Vaccine Market Size by End User
4.2.1 Global Pneumococcal Vaccine Market Size Overview by End User (2018-2029)
4.2.2 Global Pneumococcal Vaccine Historic Market Size Review by End User (2018-2023)
4.2.3 Global Pneumococcal Vaccine Forecasted Market Size by End User (2024-2029)
4.3 Key Regions Market Size Segment by End User
4.3.1 North America Pneumococcal Vaccine Sales Breakdown by End User (2018-2023)
4.3.2 Europe Pneumococcal Vaccine Sales Breakdown by End User (2018-2023)
4.3.3 Asia-Pacific Pneumococcal Vaccine Sales Breakdown by End User (2018-2023)
4.3.4 Latin America Pneumococcal Vaccine Sales Breakdown by End User (2018-2023)
4.3.5 Middle East and Africa Pneumococcal Vaccine Sales Breakdown by End User (2018-2023)
5 North America Pneumococcal Vaccine by Country
5.1 North America Pneumococcal Vaccine Historic Market Size by Country
5.1.1 North America Pneumococcal Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Pneumococcal Vaccine Sales in Volume by Country (2018-2023)
5.1.3 North America Pneumococcal Vaccine Sales in Value by Country (2018-2023)
5.2 North America Pneumococcal Vaccine Forecasted Market Size by Country
5.2.1 North America Pneumococcal Vaccine Sales in Volume by Country (2024-2029)
5.2.2 North America Pneumococcal Vaccine Sales in Value by Country (2024-2029)
6 Europe Pneumococcal Vaccine by Country
6.1 Europe Pneumococcal Vaccine Historic Market Size by Country
6.1.1 Europe Pneumococcal Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Pneumococcal Vaccine Sales in Volume by Country (2018-2023)
6.1.3 Europe Pneumococcal Vaccine Sales in Value by Country (2018-2023)
6.2 Europe Pneumococcal Vaccine Forecasted Market Size by Country
6.2.1 Europe Pneumococcal Vaccine Sales in Volume by Country (2024-2029)
6.2.2 Europe Pneumococcal Vaccine Sales in Value by Country (2024-2029)
7 Asia-Pacific Pneumococcal Vaccine by Region
7.1 Asia-Pacific Pneumococcal Vaccine Historic Market Size by Region
7.1.1 Asia-Pacific Pneumococcal Vaccine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Pneumococcal Vaccine Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Pneumococcal Vaccine Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Pneumococcal Vaccine Forecasted Market Size by Region
7.2.1 Asia-Pacific Pneumococcal Vaccine Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Pneumococcal Vaccine Sales in Value by Region (2024-2029)
8 Latin America Pneumococcal Vaccine by Country
8.1 Latin America Pneumococcal Vaccine Historic Market Size by Country
8.1.1 Latin America Pneumococcal Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Pneumococcal Vaccine Sales in Volume by Country (2018-2023)
8.1.3 Latin America Pneumococcal Vaccine Sales in Value by Country (2018-2023)
8.2 Latin America Pneumococcal Vaccine Forecasted Market Size by Country
8.2.1 Latin America Pneumococcal Vaccine Sales in Volume by Country (2024-2029)
8.2.2 Latin America Pneumococcal Vaccine Sales in Value by Country (2024-2029)
9 Middle East and Africa Pneumococcal Vaccine by Country
9.1 Middle East and Africa Pneumococcal Vaccine Historic Market Size by Country
9.1.1 Middle East and Africa Pneumococcal Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Pneumococcal Vaccine Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Pneumococcal Vaccine Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Pneumococcal Vaccine Forecasted Market Size by Country
9.2.1 Middle East and Africa Pneumococcal Vaccine Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Pneumococcal Vaccine Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer Pneumococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pfizer Pneumococcal Vaccine Products Offered
10.1.5 Pfizer Recent Development
10.2 GSK
10.2.1 GSK Company Information
10.2.2 GSK Introduction and Business Overview
10.2.3 GSK Pneumococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 GSK Pneumococcal Vaccine Products Offered
10.2.5 GSK Recent Development
10.3 MSD
10.3.1 MSD Company Information
10.3.2 MSD Introduction and Business Overview
10.3.3 MSD Pneumococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 MSD Pneumococcal Vaccine Products Offered
10.3.5 MSD Recent Development
10.4 Sanofipasteur
10.4.1 Sanofipasteur Company Information
10.4.2 Sanofipasteur Introduction and Business Overview
10.4.3 Sanofipasteur Pneumococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Sanofipasteur Pneumococcal Vaccine Products Offered
10.4.5 Sanofipasteur Recent Development
10.5 CDIBP
10.5.1 CDIBP Company Information
10.5.2 CDIBP Introduction and Business Overview
10.5.3 CDIBP Pneumococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.5.4 CDIBP Pneumococcal Vaccine Products Offered
10.5.5 CDIBP Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Pneumococcal Vaccine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Pneumococcal Vaccine Industrial Chain Analysis
11.4 Pneumococcal Vaccine Market Dynamics
11.4.1 Pneumococcal Vaccine Industry Trends
11.4.2 Pneumococcal Vaccine Market Drivers
11.4.3 Pneumococcal Vaccine Market Challenges
11.4.4 Pneumococcal Vaccine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Pneumococcal Vaccine Distributors
12.3 Pneumococcal Vaccine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
